Abstract
The study aimed to prepare and characterize the formononetin-2-hydroxypropyl-β-cyclodextrin inclusion complex loaded PLGA nanoparticles (FMN-2-HPβ-CD-NP). The neutralization agitation method was used to prepare FMN-2-HPβ-CD inclusion complex. Phase solubility study demonstrated the formation of AL type inclusion complex. The inclusion stability constant was 2116 ± 73 M−1. The PLGA nanoparticles were prepared by solid/oil/water (S/O/W) technology and theirs in vitro properties were studied. Experiments of NMR, FTIR, XRD and SEM confirmed the formation of FMN-2-HPβ-CD inclusion complex. Transmission electron microscopy (TEM) showed the spherical morphology of FMN-2-HPβ-CD-NP. The average particle size was 210.23 ± 3.4 nm, the polydispersity index was 0.108 ± 0.02, the Zeta potential was −26.25 ± 0.42 mV and the mean encapsulation efficiency was 91.97± 0.79%. The in vitro release study indicated that FMN-2-HPβ-CD-NP had a sustained release effect. The in vitro cytotoxicity showed that FMN-2-HPβ-CD-NP remained anticancer activity in Hela and MCF-7 tumor cells compared to free FMN. In conclusion, the novel delivery system of drug-in-cyclodextrin-in-nanoparticles was a promising carrier for poor lipophilic and poor hydrophilic drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
